Kelly M. Brunk: Immunotherapy success for HIV-positive cancer patient
Kelly M. Brunk, Senior Manager of Clinical Initiatives at NCODA, posted the following on LinkedIn:
“Excited to share our latest case report, co-authored with my colleagues from the University of Kansas Cancer Center!
We followed the journey of a 58-year-old man with HIV and a CD4 count of 53 cells/mm³, diagnosed with stage 4 left frontotemporal squamous cell carcinoma. After his cancer recurred following initial treatments, he started pembrolizumab therapy.
Incredible results: A complete response was observed just 83 days in, lasting for a year, even with low CD4 counts. This case highlights that immunotherapy can be both safe and effective for solid organ malignancies in HIV-positive patients.
We hope our findings inspire further research in this area.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023